NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)
NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5